Merck pairs up for Keytruda diagnostic; Multivir scraps IPO plot;

@FierceBiotech: The White House draws the line against CRISPR/Cas9-designed embryos. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: Seres ($MCRB), joins $ADAP, $ADRO, $CDTX, $JUNO, Molecular Partners and $ONCE among the 2014 Fierce 15 biotechs to go for an IPO. | Follow @JohnCFierce

> Merck ($MRK) inked a deal with diagnostics outfit NanoString Technologies ($NSTG) to craft an assay that will help identify ideal patients for Keytruda, the drugmaker's blockbuster-in-waiting cancer immunotherapy. More

> MultiVir, a gene therapy biotech formerly known as Introgen Therapeutics, nixed its plans to raise $60 million in an IPO. News

> Ultragenyx Pharmaceutical ($RARE) kicked off a Phase III trial of its extended-release aceneuramic acid, a treatment for a rare, muscle-destroying disease called GNE myopathy. Item

Medical Device News

@FierceMedDev: Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery report | Follow @VarunSaxena2

@EmilyWFierce: $SQNM is consolidating its labs. Release | Follow @EmilyWFierce

> Freedom Meditech, maker of diabetes eye scanner, raises $4.8M in Series C round. Article

> WSJ: J&J faces FBI probe over power morcellator devices. Report

Pharma News

@FiercePharma: ICYMI: As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO says. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Top Medicare prescribers get top payments from drugmakers: Modern Healthcare. Report | Follow @CarlyHFierce

> FTC scores hefty $1.2B settlement in Teva pay-for-delay case. Report

> GI dealmaking pays off for Valeant, Actavis with same-day FDA nods in IBS. Story

Vaccines News

> World Health Assembly passes resolution on vaccine pricing, transparency. Item

> Serum Institute, Cipla partner to market flu vaccine in India. More

> Abivax seeks cash to bring Cuban-discovered HepB vaccine to the world. Story

> Hold the offer: Bavarian Nordic declares it's not for sale. Article

> Regeneus gets green light to move personalized cancer vaccine into PhI. Report

CRO News

> Parexel rejigs its randomization tech with an eye on speed. Item

> BioClinica partners up for risk-based management. More

> Ergomed snags a postmarketing firm with its eye on pharmacovigilance. Article

> EMA still wants 700 GVK-related drugs off the market. Story

> Quintiles homes in on Asian biotech with its latest offering. Report

Pharma Manufacturing News

> Bayer set to spend $3.4M this year to expand its Indonesian operations. Story

> Report: Claris Lifesciences injectables sale may hit roadblock by FDA Form 483. Item

> Aurobindo Pharma submits abbreviated application to FDA for HIV drug production. News

> Gerresheimer Glass to close NJ pharmaceutical bottle plant this summer. Article

> Gilead Sciences plans $100M expansion of Edmonton plant. Report

Pharma Asia News

> Singapore clinical hub to work with Visterra on dengue candidate. More

> TPP negotiators said to be zeroing in on clearing IP snags. Story

> Japan's cabinet tells health minister to dig deeper on costs. Article

> China to charge $102K for drug, device registration in first hike in two years. Item

> Russia makes it easier to skirt imported drug sale norms. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.